Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients …
Full ANRO analysis →
Competitive advantage assessment
Key strengths
Strong Liquidity BufferLiquidity position is strong (score 0.93), providing operational cushion.
Key risks
ROIC Below WACC or PeersROIC at 0th percentile suggests inefficient capital deployment.
Weak or Negative Cash FlowCash generation is weak (score 0.00), limiting financial flexibility.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Alto Neuroscience, Inc. ranks #423 of 713
scored companies in Biotechnology by moat score — the top 59%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near ANRO in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Not measurable
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Not measurable
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 19
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 63
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Not measurable
· 15% of the moat score
Scale matters only when it converts into economics.
Alto Neuroscience, Inc. (ANRO) scores 36 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #423 of 713 scored companies in Biotechnology, the top 59%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (63/100) and its weakest is Capital Efficiency (19/100).
How does Alto Neuroscience, Inc. compare with other Biotechnology companies?
Alto Neuroscience, Inc. ranks #423 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Zura Bio Limited (ZURA) at 36 just above it and ProKidney Corp. (PROK) at 36 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Alto Neuroscience, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Alto Neuroscience, Inc.?
The Corporate Default template measures 6 defenses, and ANRO scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (19), Resilience (63), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.